Holen Sie sich die Stockscreener-App
0.00
100.00%
-27.73
Schlusskurs vom Vortag:
$27.73
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$1.83B
Einnahmen:
$1.28B
Nettoeinkommen (Verlust:
$391.32M
KGV:
0.00
EPS:
5.9613
Netto-Cashflow:
$-238.89M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$37.78
Galapagos Nv Adr Stock (GLPG) Company Profile
Firmenname
Galapagos Nv Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare GLPG vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLPG
Galapagos Nv Adr
|
0.00 | 1.83B | 1.28B | 391.32M | -238.89M | 5.9613 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-02-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-11-20 | Herabstufung | Kepler | Hold → Reduce |
| 2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-08-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-03-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-08-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-23 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-11-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-19 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-08-06 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
| 2021-04-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-02-19 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-19 | Eingeleitet | Maxim Group | Buy |
| 2020-10-21 | Herabstufung | Goldman | Neutral → Sell |
| 2020-08-25 | Herabstufung | Jefferies | Buy → Hold |
| 2020-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-08-19 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-08-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-07-10 | Herabstufung | Stifel | Buy → Hold |
| 2020-03-30 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-18 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2020-02-25 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-02-24 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-01-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-12-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-12-02 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-07-31 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-29 | Herabstufung | Jefferies | Buy → Hold |
Alle ansehen
Galapagos Nv Adr Aktie (GLPG) Neueste Nachrichten
Why Is Galapagos N.V. Sponsored ADR (LKFT) Stock Up Today? - Meyka
Why Is Galapagos N.V. Sponsored ADR (LKFT) Stock Down Today? - Meyka
Galapagos N.V. Sponsored ADR (LKFT) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
LKFT Stock Price, Quote & Chart | LAKEFRONT BIOTHERAPEUTIC-ADR (NASDAQ:LKFT) - ChartMill
GLPG SEC FilingsGalapagos Nv 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings call transcript: Galapagos NV sees 91% revenue drop in Q1 2026 - Investing.com
Earnings call transcript: Galapagos NV sees 91% revenue drop in Q1 2026 By Investing.com - Investing.com South Africa
Galapagos NV Sponsored ADR (LKFT) Stock Live Price, Chart & News - CoinCodex
Lakefront Biotherapeutics (NASDAQ: GLPG) outlines ADR deposit terms - Stock Titan
LKFT Stock Price and Chart — NASDAQ:LKFT - TradingView
LKFT Stock Price and Chart — EURONEXT:LKFT - TradingView
Galapagos Q1 2026 presentation: Ouro deal, rebranding highlight transformation By Investing.com - Investing.com South Africa
Earnings call transcript: Galapagos Q1 2026 beats EPS, revenue falls short By Investing.com - Investing.com South Africa
Earnings call transcript: Galapagos Q1 2026 beats EPS, revenue falls short - Investing.com
Galapagos Q1 2026 presentation: Ouro deal, rebranding highlight transformation - Investing.com
Galapagos (GLPG) posts Q1 2026 profit and commits up to €790M to Ouro deal - Stock Titan
GLPG.AS Stock Price, Quote & Chart | GALAPAGOS NV (AMS:GLPG) - ChartMill
GLPG Stock Price, Quote & Chart | GALAPAGOS NV-SPON ADR (NASDAQ:GLPG) - ChartMill
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - Benzinga
Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition - Sahm
ETFs Investing in Galapagos NV Sponsored ADR Stocks - TradingView
Galapagos FY 2025 slides: €3B cash fuels transformation strategy - Investing.com Australia
RBC Capital raises Galapagos stock price target to $33 on model updates - Investing.com South Africa
Earnings call transcript: Galapagos Q4 2025 earnings surpass expectations, stock rises By Investing.com - Investing.com South Africa
Galapagos stock rating reiterated at Market Perform by Raymond James - Investing.com
Galapagos FY 2025 slides: €3B cash fuels transformation strategy By Investing.com - Investing.com South Africa
Earnings call transcript: Galapagos Q4 2025 earnings surpass expectations, stock rises - Investing.com
Earnings Breakdown: Galapagos Q4 - Sahm
A Peek at Galapagos's Future Earnings - Sahm
Stock Market Today: Nasdaq Futures Pare Losses, Dow Drops After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus (UPDATED) - Benzinga
Stock Market Today: Dow Jones Futures Drop After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus - Sahm
AngioDynamics, Microchip Technology And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Galapagos stock holds steady as Raymond James maintains Market Perform rating - Investing.com
Bernstein initiates Market Perform rating on Galapagos stock with EUR27.90 target - Investing.com
Earnings call transcript: Galapagos Q3 2025 sees earnings miss, stock steady - Investing.com
Galapagos stock price target raised to $28 from $27 at RBC Capital - Investing.com
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks - Benzinga
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Pharvaris (PHVS) and Stevanato Group (STVN) - The Globe and Mail
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - TechStock²
Galapagos NV (GLPG)' CAR-T Therapy Hits 97% Response Rate in Lymphoma Trial - Finviz
Raymond James reiterates Market Perform rating on Galapagos stock - Investing.com
GLPG Stock Price, News & Analysis - Stock Titan
Galapagos To Spin Off Innovative Medicines Business - Forbes
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com UK
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
ProShares Ultra Nasdaq Biotechnology Holdings - Quiver Quantitative
Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Billionaire hedge fund manager David Einhorn’s portfolio revealed - Daily Investor
What is the current Price Target and Forecast for Galapagos (GLPG) - Zacks Investment Research
BeiGene Ltd. (BGNE) Share Price, Stock Analysis, Annual Report - Value Research
Finanzdaten der Galapagos Nv Adr-Aktie (GLPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):